Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells

Asymmetrex Publishes the First Report of Immortal DNA Strands in Human Stem Cells

On November 13, stem cell biotechnology company Asymmetrex published a seminal research report confirming the presence of immortal DNA strands in human tissue stem cells. Immortal DNA strands are the molecular basis for the immortality of tissue stem cells. What does it mean for multiplying cells in the body to be immortal? The cell DNA

New Asymmetrex Technologies Featured in RegMedNet

New Asymmetrex Technologies Featured in RegMedNet

Read Asymmtrex’s latest article in RegMedNet to learn more about its newest technologies, the TORTOISE TestTM and RABBIT CountTM, for analytical and rapid stem cell counting through computing. The TORTOISE TestTM is a tool for tissue stem cell-specific kinetics analyses, and the RABBIT CountTM is a tool for routine rapid tissue stem cell counting. Learn more

Asymmetrex Report is the OBM Transplantation Special Issue Cover Story

Asymmetrex Report is the OBM Transplantation Special Issue Cover Story

Asymmetrex recently wrote a report, A Computational Simulation Technology for Specific Counting of Perinatal and Postnatal Human Tissue Stem Cells for Transplantation Medicine, that was published as the cover story in OBM Transplantation Special Issue: Isolation and Characterization of Adult Therapeutic Cells. Read this detailed report to learn more about how the integration of principles

Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials

Asymmetrex Presents the Value of Tissue Stem Cell Counting For Supplying Stem Cell Clinical Trials and Drug Development Clinical Trials

On September 30, stem cell biotechnology company Asymmetrex presented at the 2020 Outsourcing in Clinical Trials USA Virtual Conference. In addition to discussing the value of tissue stem cell counting for better practices in stem cell and gene therapy clinical trials, Asymmetrex director James Sherley also highlighted value that stem cell counting technologies can impart

Asymmetrex Director Interviewed by Tech Company News About Recent Grant Award

Asymmetrex Director Interviewed by Tech Company News About Recent Grant Award

Asymmetrex recently received a $0.42 million award from the NIH-National, Heart, Lung, and Blood Institute to support technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. Tech Company News reached out to Asymmetrex Director James L. Sherley to interview him about this achievement and how the

Asymmetrex Receives $0.42 Million Award from the NIH-National Heart, Lung, and Blood Institute to Develop the AlphaSTEM Test™ for Stem Cell Therapies and Drug Evaluations

Asymmetrex Receives $0.42 Million Award from the NIH-National Heart, Lung, and Blood Institute to Develop the AlphaSTEM Test™ for Stem Cell Therapies and Drug Evaluations

On September 19, 2020, stem cell biotechnology company Asymmetrex was awarded a research and development grant from the NIH-NHLBI. The $0.42 million grant was awarded to support the company’s technical development and commercialization of its first-in-kind technology for specific and accurate counting of therapeutic tissue stem cells. On the heals of Asymmetrex’s recently published peer-reviewed report describing its development

New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells

New Report Begins a New Era of Stem Cell Science and Medicine: Stem Cell Biotechnology Company Asymmetrex Tells How It Counts Therapeutic Tissue Stem Cells

In an August 28 special issue of the peer-reviewed online journal OBM Transplantation, stem cell biotechnology company Asymmetrex has now published a report describing how its technology for determining the specific dosage of therapeutic tissue stem cells works. The new technology is poised to revolutionize stem cell science and stem cell medicine by giving the